Clinical trials
Neuromyelitis Optica Spectrum Disorder clinical trials
Below are recruiting neuromyelitis optica spectrum disorder clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT06541626Recruiting
Study of CNS inflammatory demyelinating diseases
This study follows people with certain inflammatory conditions of the brain and spinal cord (like MS, NMOSD, or MOGAD) to learn more about their disease. If you join, you will help researchers understand these conditions better.
Guangzhou, GuangdongAges 18–65 - NCT07762872Recruiting
Satralizumab during early NMOSD attacks
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06474520Recruiting
Bovine gallstone extract for inflammatory brain disease
This trial tests a natural substance called Calculus Bovis Sativus (CBS) to see if it helps people with certain inflammatory brain conditions like multiple sclerosis, neuromyelitis optica, MOGAD, or ADEM. The goal is to find out if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT07738952RecruitingPhase 1/Phase 2
Sivelestat for neuromyelitis optica spectrum disorder relapses
This study tests a drug called sivelestat for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a relapse. The drug may help reduce damage during the relapse and improve recovery.
FukuokaAges 18 years+ - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07653984Recruiting
Study on immune diseases in women of childbearing age
This study follows women with certain immune disorders affecting the nervous system (like multiple sclerosis or myasthenia gravis) to understand how these conditions affect reproduction. Healthy women planning pregnancy are also included for comparison.
Guangzhou, GuangdongAges 20–55 - NCT06697535RecruitingPhase 2
Study of JYP0061 for acute NMOSD attacks
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
Changsha, HunanAges 18–65 - NCT05017142Recruiting
Pediatric brain inflammation registry for Swiss patients
This study is a registry that collects health information from children and teens in Switzerland diagnosed with certain inflammatory brain and spinal cord conditions. It helps researchers understand these illnesses better over time and may guide future treatments.
Aarau, Canton of AargauAges Up to 36 years - NCT07557420RecruitingPhase 3
Ravulizumab for Neuromyelitis Optica Spectrum Disorder in Chinese Adults
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
BeijingAges 18–130 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07420296RecruitingPhase 3
Modified zipper therapy for AQP4-positive neuromyelitis optica
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
TianjinAges 18–80 - NCT07410039RecruitingPhase 4
Acute treatment for neuromyelitis optica in real-world setting
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
BeijingAges 18–65 - NCT07377305Recruiting
Brain stimulation for nerve pain in NMOSD
This trial tests a new, non-invasive brain stimulation method (tTIS) to treat chronic nerve pain in people with neuromyelitis optica spectrum disorder (NMOSD). It aims to see if this treatment is safe and can reduce pain without surgery or drugs.
Xi'an, ShaanxiAges 18–75 - NCT06865274Recruiting
A look at gene changes in MS, NMOSD, and MOGAD
This study looks at a specific gene change in people with MS, NMOSD, or MOGAD to see how common it is. By joining, you help researchers learn more about these conditions and possible future treatments.
Roma, RomaAges 18 years+ - NCT06780709Recruiting
Wellness program for neuromyelitis optica patients
This trial tests a structured wellness program to improve quality of life for people with neuromyelitis optica (NMOSD). It is designed to be accessible for any level of disability.
New York, New YorkAges 18 years+ - NCT07202494Recruiting
Brain aging and resilience MRI study
This study uses powerful MRI scans to understand how the brain ages and why some people stay healthy while others develop neurological diseases like multiple sclerosis or Alzheimer's. It compares healthy volunteers to people with certain conditions, and all participants get a detailed brain MRI.
MarseilleAges 18–90 - NCT06763848Recruiting
Blood filtering for NMOSD attacks
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
Guangzhou, GuangdongAges 18–65 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT06939166RecruitingEarly Phase 1
Immune cell therapy for relapsed neurological autoimmune diseases
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06829524Recruiting
Study of satralizumab for NMOSD (real world evidence)
This study looks at how well satralizumab works in people with NMOSD (a rare disorder that affects the nerves in your eyes and spine). It is for people who have had recent flare-ups and test positive for a specific antibody (AQP4). You will receive satralizumab and be followed for at least one year to see if your disease stays under control.
Shanghai, Shanghai MunicipalityAges 12 years+ - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06643858Enrolling by invitation
Normal Chinese Lifespan Brain Chart Study
This study creates a 'normal brain map' by taking MRI scans of healthy people of all ages. It helps doctors understand what a healthy brain looks like at different stages of life.
Beijing, Beijing MunicipalityAges 6–90 - NCT06620809RecruitingPhase 1
New treatment for neuromyelitis optica flare-ups
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
Wuhan, HubeiAges 18–65
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Neuromyelitis Optica Spectrum Disorder trials by city
Studies with a site in or near these metro areas.
Neuromyelitis Optica Spectrum Disorder trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for neuromyelitis optica spectrum disorder?
- Yes. Clin2 currently lists 37 recruiting neuromyelitis optica spectrum disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuromyelitis optica spectrum disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuromyelitis optica spectrum disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.